Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Molecular imaging pinpoints inflammation in the brains of schizophrenics and migraine sufferers

Inflammatory response of brain cells-as indicated by a molecular imaging technique-could tell researchers more about why certain neurologic disorders, such as migraine headaches and psychosis in schizophrenic patients, occur and provide insight into how to best treat them, according to two studies published in the November issue of the Journal of Nuclear Medicine.

31 Oct 2009

Geron plans to advance clinical program for spinal cord injury

Geron Corporation today announced the company’s plan to advance clinical development of its human embryonic stem cell (hESC)-based product, GRNOPC1, for the treatment of spinal cord injury.

31 Oct 2009

Bayer HealthCare's Phase II study results of imaging agent florbetaben

Bayer HealthCare presented results from a global Phase II study of florbetaben, its imaging agent in development for the detection of cerebral beta-Amyloid plaques, at the 19th World Congress of Neurology (WCN).

30 Oct 2009

sanofi-aventis reports financial results for the third quarter of 2009

In the third quarter of 2009, sanofi-aventis generated net sales of euro 7,400 million, up 8.0% on a reported basis. Exchange rate movements had a favorable effect of 2.0 percentage points, with the appreciation of the U.S. dollar (and to a lesser extent the yen) against the euro more than offsetting the unfavorable effects of some other currencies.

30 Oct 2009

New state-of-the-art biotechnology center opened on the West Coast

As part of its strategy to discover and develop more biotechnology medicines, Eli Lilly and Company today officially opened a new state-of-the-art biotechnology center on the West Coast.

30 Oct 2009

Online resource to illustrate genetic networks in common autoimmune diseases published

Currently, 5-8% of the U.S. population is afflicted with an autoimmune disease (www.niaid.nih.gov). Many of these are chronic and require life-long care. Moreover, different autoimmune diseases aggregate within a single family, suggesting they are caused by disruptions in common biological pathways.

30 Oct 2009

Grassroots Health and the University of Toronto School of Medicine to host a Vitamin D symposium

Vitamin D Deficiency - linked to significantly higher rates of most cancers, heart disease, autoimmune diseases such as multiple sclerosis, and even flu - affects 97 per cent of Canadians. Yet fewer than 3 per cent of Canadians say they know their vitamin D blood levels.

29 Oct 2009

Fondation Jacques-F. Gougoux donates over $57,000 to the Quebec Division of the Multiple Sclerosis Society

The Quebec Division of the Multiple Sclerosis Society of Canada is delighted to be able to count on the Fondation Jacques-F. Gougoux in improving the quality of life for people with multiple sclerosis and their families. A donation of $57,386, spread over 15 years, will enable the MS Society to make some of its services more accessible.

29 Oct 2009

Montreal Chapter of the MS Society receives funds for physical activity program for people with multiple sclerosis

Under the Foundation of Greater Montreal's Community Grants Program, the Montreal Chapter of the Multiple Sclerosis Society of Canada will receive $10,000, which will ensure the continuity of its program of physical activities adapted for people with multiple sclerosis.

29 Oct 2009

AMT inks agreement with Progenika Biopharma for development of LPLchip

Amsterdam Molecular Therapeutics (AMT) and Progenika Biopharma announced today that the companies have entered into a development and commercialization agreement for LPLchip(TM), a diagnostic tool to rapidly diagnose patients with complete and partial lipoprotein lipase deficiency (LPLD). AMT has developed Glybera(R) as a gene therapy for patients with this disease.

29 Oct 2009

Gene variant may be the cause for bad driving: UC Irvine neuroscientists

Bad drivers may in part have their genes to blame, suggests a new study by UC Irvine neuroscientists.

29 Oct 2009

Veterans with TBI vision loss have poor quality of life compared to civilian patients

Pan-American Association of Ophthalmology (PAAO) Joint Meeting, includes a Veterans Administration study that indicates that Iraq and Afghanistan veterans with vision loss from traumatic brain injury have significantly poorer quality of life than comparable civilian patients, and a Harvard doctor's insights on how to best evaluate and care for low-vision patients who experience vivid visual hallucinations due to Charles Bonnet syndrome.

28 Oct 2009

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Elan Corporation, plc and Biogen Idec today announced data showing that treatment with TYSABRI® (natalizumab) significantly reduced the rate of hospitalization compared with placebo in patients with moderate–to–severe Crohn’s disease during both induction and maintenance treatment.

28 Oct 2009

Discovery of AVM can relieve pain due to chronic back pain and neurologic deficits

The discovery of a multi-level arteriovenous malformation (AVM) in the thoracic epidural space can now bring relief to potentially thousands of suffers of chronic thoracic pain and progressive myelopothy. Identified as thoracic epidural arteriovenous malformation (T.E.A.M.), this particular AMV primarily affects younger women ages 20 to 40.

27 Oct 2009

ACC's initiative for health care reform

As lawmakers debate health care reform, business innovator Lou Weisbach and Clinton White House health care advisor Dr. Richard Boxer are available for interviews to discuss a glaring, missing element of the forthcoming health care legislation: reducing health care costs -- and saving lives -- by preventing and curing disease.

27 Oct 2009

BioMarin Pharmaceutical announces the acquisition of Huxley Pharmaceuticals

BioMarin Pharmaceutical Inc. announced today that it has acquired Huxley Pharmaceuticals, Inc. (Huxley), which has rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).

27 Oct 2009

CMSC analyses patient self-management in Multiple Sclerosis

The Consortium of Multiple Sclerosis Centers (CMSC) released a white paper, written by a panel chaired by CMSC member Robert T. Fraser, Ph.D., of the University of Washington Rehabilitation Research and Training Center in Seattle, Washington, analyzing patient self-management in Multiple Sclerosis (MS) to develop recommendations for best practices aimed at improving patients' lives.

26 Oct 2009

Study: High protein levels are associated with heart attack and not stroke

People with high levels of a protein called C-reactive protein (CRP), a marker for inflammation in the blood, may be at higher risk for heart attack and death but not stroke, according to a study published in the October 20, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology.

26 Oct 2009

Eurogentec to acquire Anaspec, a private proteomics company in California

Eurogentec S.A. (“Eurogentec”) announces today a final agreement for the acquisition of AnaSpec, Inc. (“AnaSpec” or the “Company”), a privately-held proteomics company based in Fremont, California.

24 Oct 2009

University neurologists launch multiple sclerosis research study

Neurologists at the University at Buffalo are beginning a research study that could overturn the prevailing wisdom on the cause of multiple sclerosis (MS).

24 Oct 2009